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Summary Recent observations have shown that the pineal hormone melatonin (MLT) may modulate
oestrogen receptor (ER) expression and inhibit breast cancer cell growth. On this basis, we have evaluated the
biological and clinical effects of a concomitant MLT therapy in women with metastatic breast cancer who had
progressed in response to tamoxifen (TMX) alone. The study included 14 patients with metastasis who did not
respond (n = 3) to therapy with TMX alone or progressed after initial stable disease (SD) (n = 11). MLT was
given orally at 20 mg day-' in the evening, every day starting 7 days before TMX, which was given orally at
20 mgday-' at noon. A partial response was achieved in 4/14 (28.5%) patients (median duration 8 months).
The treatment was well tolerated in all cases, and no MLT-induced enhancement of TMX toxicity was seen;
on the contrary, most patients experienced a relief of anxiety. Mean serum levels of insulin-like growth factor
I (IGF-1), which is a growth factor for breast cancer, significantly decreased on therapy, and this decline was
significantly higher in responders than in patients with SD or progression. This pilot phase II study would
suggest that the concomitant administration of the pineal hormore MLT may induce objective tumour
regressions in metastatic breast cancer patients refractory to TMX alone.
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Several experimental studies have demonstrated that the anti-
oestrogenic action is only one of the great variety of
mechanisms responsible for the antineoplastic properties of
tamoxifen (TMX) in breast cancer. Oestrogens themselves
would stimulate breast cancer growth by determining the
paracrine release of growth factors, such as insulin-like
growth factor 1 (IGF-1) (Furlanetto and Decarlo, 1984; Duc-
los et al., 1989). Recent investigations have shown that breast
cancer cells may express IGF-1 receptors (Bonneterre et al.,
1990), and their presence seems to have a positive prognostic
significance. Moreover, it has been demonstrated that TMX
therapy reduces IGF-1 blood levels in breast cancer patients,
and this event may contribute to the therapeutic effect of
TMX itself (Pollak et al., 1990). Another growth factor for
breast cancer is prolactin (PRL). High levels of PRL have
been proven to be associated with a poor prognosis in metas-
tatic breast cancer patients (Bhatavdekar et al., 1990), while
the expression of PRL receptor on breast cancer cells cons-
titutes a good prognostic factor (Bonneterre and Peyrat,
1989). However, the role of PRL and PRL receptor in breast
cancer is still controversial.
Recent advances in endocrinology have documented that
the endocrine secretions are under a modulatory control
exerted by the pineal gland (Regelson and Pierpaoli, 1987),
mainly through the circadian release of its most investigated
hormone melatonin (MLT). MLT has been proven to
stimulate oestrogen receptor (ER) expression on breast
cancer cells (Danforth et al., 1983) and to reverse some
malignant phenotypic characteristics of cancer cells (Hill and
Blask, 1988), perhaps by inhibiting oncogene expression,
which would be responsible for the malignant characteristics
themselves. Finally, MLT appears to inhibit the secretion of
IGF-I and PRL (Regelson and Pierpaoli, 1987), both
involved in the stimulation of breast cancer cell proliferation.
Other endocrine secretions are influenced by MLT, partic-
ularly growth hormone and cortisol (Regelson and Pierpaoli,
1987). Therefore, several effects exerted by MLT, consisting
in stimulation of ER expression and inhibition of IGF-I
production and PRL release, would suggest that the pineal
hormone may potentiate TMX therapeutic efficacy. In fact,
preliminary experimental studies have demonstrated that
MLT may amplify in vitro TMX-induced inhibition of breast
cancer cell growth (Hill et al., 1992). In addition, MLT has
been proven to have a direct cytostatic action against some
breast cancer cell lines (Hill and Blask, 1988). The present
phase II study was performed to investigate the biological
and therapeutic effects of a concomitant administration of
MLT in metastatic breast cancer patients who progressed
under therapy with TMX alone.
Patients and methods
The study included 14 consecutive women with metastatic
breast cancer who did not respond to TMX therapy or
progressed after initial disease stabilisation. Dominant metas-
tasis sites were as follows: soft tissues, 3; bone, 4; visceral
locations, 7 (lung, 3; pleural space, 2; liver, 2). ER estimation
was made on the primary tumour by the dextran-coated
charcoal method; ER was considered as positive when values
were greater than 10 fmol mg-' protein. ER was positive in
eight and negative in the other six cases. Patients with
negative ER had been also treated with TMX since they were
unable to tolerate conventional polychemotherapy because of
age, low performance status (PS) and/or important medical
illnesses other than cancer. The previous therapy with TMX
alone resulted in stabilisation of disease in 11 patients
(median duration 8 months, range 3-16), whereas the other
three patients rapidly progressed on treatment. Eligibility
criteria included histologically proven breast cancer, metas-
tatic disease, measurable lesions, progression on TMX
therapy alone and inability to tolerate conventional
polychemotherapies because of age and/or concomitant
medical illnesses. The experimental protocol was explained to
each patient, and informed consent was obtained. TMX was
given orally at a daily dose of 20 mg at 12.00 a.m., every day
until progression. MLT, which was supplied by Medea
Research (Milan, Italy), was administered orally at a daily
dose of 20 mg in the evening every day of TMX therapy
starting 7 days before TMX, as an induction phase. The dose
of MLT was established from our previous studies (Lissoni et
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November 1994.al., 1989, 1991). Moreover, MLT was given during the dark
period of the day because of its greater biological efficacy in
this period of the day (Regelson and Pierpaoli, 1987). All
patients had been off TMX for at least 1 month (median
period 2 months, range 1-3) before starting MLT plus TMX
therapy.
Radiological examinations were made before the onset of
treatment, after each month of therapy for the first 3 months,
then every 3 months. Clinical response and toxicity were
evaluated according to UICC and WHO criteria respectively.
All responses were confirmed by computerised tomographic
(CT) scan. Complete response (CR) was defined as a com-
plete regression of all lesions for at least 1 month; partial
response (PR) was considered as a reduction of at least 50%
in the sum of the products of the longest perpendicular
diameters for at least 1 month; stable disease (SD) was
defined as no objective cancer regression or increase greater
than 25%; progressive disease (PD) was an increase of at
least 25% in measurable lesions or the appearance of new
lesions. Patients were considered as evaluable when they were
treated for at least 2 months. PS was evaluated according to
Karnofsky's score.
Routine laboratory tests were repeated at weekly intervals
for the first 3 months, then every month. Moreover, serum
levels of IGF-1 and PRL were also measured before treat-
ment and at 1 month intervals for the first 3 months. IGF-l
and PRL serum levels were measured in duplicate by the
radioimmunoassay (RIA) method and commercially available
kits. Intra-assay and inter-assay coefficients of variation were
less than 3% and 5% respectively. Normal values obtained in
our laboratory (95% confidence limits) for IGF-1 and PRL
were less than 2.2 Uml' and less than 20 ng ml-' respec-
tively. Data were statistically analysed by the chi-square test,
the Student's t-test and analysis of variance as appropriate.
Results
The characteristics of patients and their clinical response are
reported in Table I. All patients were evaluable for response.
No CR was achieved. PR was obtained in four patients
(28.5%) (median duration: 8 months, range 3-9). The first
two patients had single lung nodular metastasis; the third
patient showed a cytologically positive pleural effusion and
pleural infiltration documented by CT scan; the last patient
had multiple skin metastases. No significant difference in
tumour response rate was seen between patients with positive
and negative ER (2/8 vs 2/6). Eight other patients had SD,
whereas the remaining two patients had progression. All
patients were followed-up for at least 1 year. Survival for
longer than 1 year from the onset of treatment was observed
in 10/14 patients.
No toxicity was found. On the contrary, most patients
experienced a relief of anxiety; moreover, a relief of depres-
sant symptoms occurred in 3 patients. Finally, two other
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patients with low PS, as evaluated according to Karnofsky's
score, had a clear improvement in their PS and quality of life
on treatment. The improvement in the quality of life was
based on specific patient report.
Changes in mean serum levels of IGF-1 observed on study
are illustrated in Figure 1. Mean concentrations of IGF-1
significantly decreased on treatment with respect to the
values found before therapy. Moreover, minimum values
(mean ± s.e.) of IGF-1 levels observed on therapy were
significantly lower in patients who responded than in those
with SD or progression (0.7 ± 0.3 vs 3.1 ± 0.6 Uml1,
P<0.05), whereas no significant difference was seen before
therapy (3.9 ± 0.6 vs 4.7 ± 0.9). Mean PRL levels also
significantly decreased on treatment with respect to the
pretreatment ones (13 ± 2 vs 25 ± 3 ngml-', P<0.05), even
though no difference was observed in mean PRL decrease
between responding patients and those with progression or
SD (14±5 vs 11±4ngml-').
Discussion
This preliminary phase II study would suggest that the pineal
hormone MLT may amplify the therapeutic efficacy of TMX
in women with metastatic breast cancer and induce objective
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Figure 1 Serum levels (mean ± s.e.) of insulin-like growth factor
1 (IGF-1) before and under treatment with tamoxifen plus
melatonin in 14 woman with metastatic breast cancer. *P<O.OS
vs before. **P<0.01 vs before.
Table I Clinic characteristics of 14 women with breast cancer and their clinical response to tamoxifen (TMX plus melatonin)
Patient Sites of Previous response to Clinical Time to progression Sites of Sites of Survival
no. Age metastases ER TMX alone (+) response (months) response progression (months)
1 65 Bone + SD ( 6) SD 3 - Liver 8
2 63 Pleura + SD (13) SD 3 - Pleura 7
3 59 Lung - SD ( 8) PR 7 Lung Skin 17+
4 67 Bone - SD (8) SD 4 - Bone 16+
5 42 Liver, bone + SD ( 3) SD 3 - Bone 15+
6 74 Pleura + SD ( 9) PR 8 Pleura Bone 15+
7 80 Lung + SD (16) PR 6 Lung Lung 14+
8 59 Skin - SD ( 4) PD - - Skin 7
9 72 Bone + SD (14) SD 4 - Bone 14
10 76 Liver, bone - SD ( 5) SD 8 - Liver 13
11 38 Lung, bone + PD PD - - Bone 13+
12 74 Skin - PD SD 9 - Bone 14+
13 58 Skin - PD PR 9 Skin Bone 13+
14 72 Bone + PD SD 5 - Lung 11
ER, estrogen receptor, PR, partial response; SD, stable disease, PD, progressive disease; +, time to progression (months) under TMX alone.
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tumour regressions in patients who have not responded to
previous therapy with TMX alone irrespective of ER status.
However, measurements of other prognostic variables, such
as progesterone and MLT receptors, will have to be
evaluated to better define possible predictive factors for MLT
efficacy. Therefore, because of its complete lack of toxicity,
the combination of TMX and MLT could constitute a new
effective modality of therapy for metastatic breast cancer,
particularly in patients unable to tolerate conventional
chemotherapies. Moreover, the results ofthis study, by show-
ing declines in blood levels of tumour growth factors IGF-I
and PRL, would suggest that MLT may amplify TMX
activity by blocking the production of important growth
factors for breast cancer. However, the IGF-1 decrease
observed in this study may be due not only to MLT action,
but also at least in part to TMX itself, since TMX has been
proven to inhibit IGF-I secretion (Pollak et al., 1990). In any
case, the action of MLT on IGF-I secretion could explain
the potential efficacy of the pineal hormone in patients with
negative ER states. Recently, MLT receptors have been
documented on some cancer cell lines (Hill et al., 1992).
Therefore, further studies, by investigating the expression of
MLT receptors and by analysing their existence in relation to
ER, PRL and IGF-1 receptors, will be required to predict the
efficacy of this pineal hormone in breast cancer. Obviously,
the small number of patients considered in this study does
not allow us to draw definite conclusions about the possible
use of MLT to modulate the efficacy of breast cancer endoc-
rine therapy. However, the evidence of objective tumour
regressions induced by concomitant MLT treatment in breast
cancer patients who did not respond to a previous therapy
with TMX alone would confirm the oncostatic properties of
MLT. This study does not allow us to establish whether
tumour regression is due to MLT alone or to its combination
with TMX. Previous studies have shown that MLT may
decrease oestrogen levels in breast cancer (Regelson and
Pierpaoli, 1987), but it is generally unable to induce objective
tumour regression as a single agent (Lissoni et al., 1989,
1991). In addition, the contribution of a TMX withdrawal
effect cannot be excluded, even though it is generally unlikely
in patients non-responsive to TMX alone. In conclusion,
randomised studies with TMX alone vs MLT alone vs their
combination will be required to better define the influence of
the pineal hormone on TMX anti-tumour activity.
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